Marcelle Machluf
Founder at NanoGhost Ltd.
Profile
Marcelle Machluf is the founder of NanoGhost Ltd.
which was founded in 2019.
She is currently an Associate Professor at Technion-Israel Institute of Technology.
Dr. Machluf was an External Director at Erech Finance Cahalacha Ltd.
from 2010 to 2019.
Dr. Machluf has an undergraduate degree from The Hebrew University of Jerusalem and graduate and doctorate degrees from Ben-Gurion University of the Negev.
Marcelle Machluf active positions
| Companies | Position | Start |
|---|---|---|
| Technion-Israel Institute of Technology | Corporate Officer/Principal | - |
NanoGhost Ltd.
 NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Founder | 2019-08-13 |
Former positions of Marcelle Machluf
| Companies | Position | End |
|---|---|---|
| ERECH FINANCE CAHALACHA LTD | Director/Board Member | 2019-10-26 |
Training of Marcelle Machluf
| Ben-Gurion University of the Negev | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ERECH FINANCE CAHALACHA LTD | Health Technology |
| Private companies | 1 |
|---|---|
NanoGhost Ltd.
NanoGhost Ltd. Packaged SoftwareTechnology Services NanoGhost Ltd. is an Israeli biotech company that specializes in developing a drug delivery platform called Nano-Ghosts/NGs. The company is based in Netanya, Israel. The platform is highly selective and is derived from the cell membrane of mesenchymal stem cells (MSCs), which have a known affinity for cancer and sites of inflammation. The company was founded in 2019 by Marcelle Machluf. Yonatan Malca has been the CEO of the company since 2019. | Technology Services |
- Stock Market
- Insiders
- Marcelle Machluf
